Rodman & Renshaw Initiates Coverage on Cleveland BioLabs (CBLI) with a Market Outperform
More News related to CBLI
- Cleveland BioLabs (CBLI) Gets Patent for Radiation Protection, Including Protectan CBLB502
- Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502
- Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference
- Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502
- Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Rodman & Renshaw initiates coverage on Cleveland BioLabs, Inc. (Nasdaq: CBLI) with a Market Outperform. Price target $8.
To see more analyst ratings on CBLI Click Here.
Cleveland Biolabs, Inc. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and other acute stresses.
Related Categories
New CoverageStocks Mentioned
-0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
